30Apr 2017

THE EFFECT OF EZETIMIBE ON GLYCEMIC PARAMETER IN IRAQI WOMEN WITH METABOLIC SYNDROME.

  • Al-Nahrain University/College of Medicine /Pharmacology Department.
  • ‎Al ‏-Yarmook ‏University collegel / Pharmacology Department.
  • Missan University/College of Medicine / Medicine Department.
  • ‎Missan University/College of Pharmacy / Pharmacology Department.
Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Metabolic syndrome is multiple clinical component that leads development of Type 2 Diabetes Mellitus, atherosclerosis and various diseases. The study included 90 female with metabolic syndrome according to International Diabetic Federation (IDF) criteria. They divided into three groups (30 patients in each group) First group put on diet restriction and physical exercise, the second group put on metformin 750 mg extended release once daily while the third group given ezetimibe 10 mg tab plus diet restriction and physical exercise.The duration of study 12 weeks ,samples taken from each patients at zero time to determine baseline level and after 12 weeks including measurements of WC,BMI,FBS,FIHOMA-IRHbA1c ,TG and HDL. Results:- Show significant changes in the measured parameter in the first group while highly significant changes in ezetimibe and metformin group Conclusion:- From these noticeable changes in the patients taken ezetimibe we conclude that ezetimibe have effect in improving glycemic parameter in Iraqi metabolic syndrome women.

  1. Alberti, K. G. M. M., P. Zimmet and J. Shaw (2006). "Metabolic syndrome?a new world‐wide definition. A consensus statement from the international diabetes federation." Diabetic medicine 23(5): 469-480.
  2. Borch-Johnsen, K. (2013). Epidemiology of the Metabolic Syndrome. The Metabolic Syndrome, Springer: 7-16.
  3. Chan, D. C., G. F. Watts, S. K. Gan, E. M. Ooi and P. H. R. Barrett (2010). "Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet." Diabetes Care 33(5): 1134-1139.
  4. Das, U. N. (2010). Metabolic syndrome pathophysiology: the role of essential fatty acids, John Wiley & Sons.
  5. Deushi, M., M. Nomura, A. Kawakami, M. Haraguchi, M. Ito, M. Okazaki, H. Ishii and M. Yoshida (2007). "Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome." FEBS letters 581(29): 5664-5670.
  6. Jenkins, A. J., P. P. Toth and T. J. Lyons (2014). "Lipoproteins in diabetes mellitus."
  7. Katzung, B. G., S. B. Masters and A. J. Trevor (2009). "Basic & clinical pharmacology."
  8. Kilpatrick, E. S., A. S. Rigby and S. L. Atkin (2007). "Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes ?double diabetes? in the Diabetes Control and Complications Trial." Diabetes care 30(3): 707-712.
  9. Laclaustra, M., D. Corella and J. M. Ordovas (2007). "Metabolic syndrome pathophysiology: the role of adipose tissue." Nutrition, metabolism and cardiovascular diseases 17(2): 125-139.
  10. Muoio, D. M. and P. D. Neufer (2012). "Lipid-induced mitochondrial stress and insulin action in muscle." Cell metabolism 15(5): 595-605.
  11. Ninomiya, J. K., G. L?Italien, M. H. Criqui, J. L. Whyte, A. Gamst and R. S. Chen (2004). "Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey." Circulation 109(1): 42-46.
  12. O'Neill, S. and L. O'Driscoll (2015). "Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies." obesity reviews 16(1): 1-12.
  13. Putnam, K., R. Shoemaker, F. Yiannikouris and L. A. Cassis (2012). "The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome." American Journal of Physiology-Heart and Circulatory Physiology 302(6): H1219-H1230.
  14. Shankar, P. and M. Sundarka (2003). "Metabolic syndrome: Its pathogenesis and management." J Indian Acad Clin Med 4: 275-281.
  15. Takase, H., Y. Dohi, T. Okado, T. Hashimoto, Y. Goto and G. Kimura (2012). "Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study." European journal of clinical investigation 42(12): 1287-1294.
  16. Thaman, R. G. and G. P. Arora (2013). "Metabolic Syndrome: Definition and Pathophysiology?the discussion goes on." Journal of Physiology and Pharmacology Advances 3(3): 48-56.
  17. Villagra, V. G. (2009). "An obesity/cardiometabolic risk reduction disease management program: a population-based approach." The American journal of medicine 122(4): I-CO4.
  18. Wisse, B. E. (2004). "The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity." Journal of the American Society of Nephrology 15(11): 2792-2800.
  19. Zimmet, P., K. G. M. Alberti and M. S. R?os (2005). "A new International Diabetes Federation (IDF) worldwide definition of the metabolic syndrome: the rationale and the results." Revista Espa?ola de Cardiolog?a (English Edition) 58(12): 1371-1375.

[Ali K. Hoshi Allami, Faruk H Al-Jawad, Yaseen O. Yaseen and M. Haider F. Shamikh. (2017); THE EFFECT OF EZETIMIBE ON GLYCEMIC PARAMETER IN IRAQI WOMEN WITH METABOLIC SYNDROME. Int. J. of Adv. Res. 5 (Apr). 1872-1884] (ISSN 2320-5407). www.journalijar.com

Haider F. Shamikh Alsaedi

DOI:

Article DOI: 10.21474/IJAR01/4025      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4025

Download Full Paper

Download PDF No. of Downloads: 16 | No. of Views: 106